Trials / Completed
CompletedNCT05628857
A Study of RC108-ADC in Subjects With Advanced Digestive System Malignant Tumor
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of RC108 for Injection in the Treatment of Patients With c-Met-positiveAdvanced Digestive System Malignant Tumor
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- RemeGen Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
A multi-center, open-label, study designed to evaluate the preliminary efficacy, safety and pharmacokinetics of RC108 in patients with c-Me-positive advanced digestive system malignancies.
Detailed description
The primary purpose of this trial is to evaluate the preliminary efficacy, safety and efficacy of RC108 in patients with c-Me positive advanced gastrointestinal malignancies such as gastric, colorectal, esophageal, hepatic, pancreatic and bile duct cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RC108 | RC108 is comprised of an antibody component conjoined to a drug component in a lyophilized powder, which is made into solution for intravenous administration. |
Timeline
- Start date
- 2022-11-11
- Primary completion
- 2025-12-31
- Completion
- 2025-12-31
- First posted
- 2022-11-29
- Last updated
- 2026-01-06
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05628857. Inclusion in this directory is not an endorsement.